{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T06:21:48Z","timestamp":1783578108565,"version":"3.55.0"},"reference-count":183,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000149","name":"Canadian Association of Gastroenterology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000149","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008021","name":"Bristol-Myers Squibb Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003037","name":"Elan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003037","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008207","name":"AstraZeneca Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008207","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008243","name":"Center for Visual Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016040","name":"Takeda Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007582","name":"Alberta Health Services","doi-asserted-by":"publisher","award":["GR"],"award-info":[{"award-number":["GR"]}],"id":[{"id":"10.13039\/100007582","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019211","name":"AbbVie Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019211","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010875","name":"Amgen Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010875","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007110","name":"Schering-Plough","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013739","name":"Pfizer Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013739","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007343","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007343","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004628","name":"MedImmune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.cgh.2019.02.043","type":"journal-article","created":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T13:38:15Z","timestamp":1551965895000},"page":"1680-1713","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn\u2019s Disease"],"prefix":"10.1016","volume":"17","author":[{"given":"Remo","family":"Panaccione","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Hillary","family":"Steinhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Bressler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4366-9076","authenticated-orcid":false,"given":"Laura","family":"Targownik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6869-0982","authenticated-orcid":false,"given":"Waqqas","family":"Afif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Bitton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9940-9054","authenticated-orcid":false,"given":"Mark","family":"Borgaonkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usha","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Halloran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0707-5294","authenticated-orcid":false,"given":"Erin","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grigorios I.","family":"Leontiadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Edward V.","family":"Loftus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Meddings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3616-9292","authenticated-orcid":false,"given":"Paul","family":"Moayyedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2765-7972","authenticated-orcid":false,"given":"Sophie","family":"Plamondon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Rosenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7026-7099","authenticated-orcid":false,"given":"David","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia H.","family":"Seow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chadwick","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles N.","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2019.02.043_bib1","doi-asserted-by":"crossref","first-page":"7272","DOI":"10.3748\/wjg.v21.i23.7272","article-title":"Prevalence and predictors of hospitalization in Crohn's disease in a prospective population-based inception cohort from 2000-2012","volume":"21","author":"Golovics","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cgh.2019.02.043_bib2","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/MIB.0000000000000608","article-title":"Mortality trends in Crohn's disease and ulcerative colitis: a population-based study in Quebec, Canada","volume":"22","author":"Bitton","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.02.043_bib3","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10620-014-3368-z","article-title":"The economic and quality-of-life burden of Crohn's disease in Europe and the United States, 2000 to 2013: a systematic review","volume":"60","author":"Floyd","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2019.02.043_bib4","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/apt.13475","article-title":"Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn's disease","volume":"43","author":"Shah","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2019.02.043_bib5","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/apt.13276","article-title":"Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy","volume":"42","author":"Gisbert","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2019.02.043_bib6","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2019.02.043_bib7","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s11136-016-1398-z","article-title":"Value redefined for inflammatory bowel disease patients: a choice-based conjoint analysis of patients' preferences","volume":"26","author":"van Deen","year":"2017","journal-title":"Qual Life Res"},{"key":"10.1016\/j.cgh.2019.02.043_bib8","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1038\/ajg.2015.321","article-title":"Inflammatory bowel disease patients' willingness to accept medication risk to avoid future disease relapse","volume":"110","author":"Bewtra","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2019.02.043_bib9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.crohns.2009.12.002","article-title":"The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management","volume":"4","author":"Dignass","year":"2010","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2019.02.043_bib10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","article-title":"3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: part 1\u2014diagnosis and medical management","volume":"11","author":"Gomollon","year":"2017","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2019.02.043_bib11","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.cgh.2019.02.043_bib12","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.cgh.2013.02.001","article-title":"The AGA institute process for developing clinical practice guidelines part one: grading the evidence","volume":"11","author":"Sultan","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.02.043_bib13","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1053\/j.gastro.2015.03.001","article-title":"Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus","volume":"148","author":"Bressler","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.02.043_bib14","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1053\/j.gastro.2014.01.042","article-title":"Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology","volume":"146","author":"Nguyen","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.02.043_bib15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.gastro.2016.04.006","article-title":"The Toronto consensus for the treatment of Helicobacter pylori infection in adults","volume":"151","author":"Fallone","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.02.043_bib16","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.gastro.2015.12.003","article-title":"The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy","volume":"150","author":"Nguyen","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.02.043_bib17","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jclinepi.2014.12.011","article-title":"Guideline panels should not GRADE good practice statements","volume":"68","author":"Guyatt","year":"2015","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.cgh.2019.02.043_bib18","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S0016-3287(69)80025-X","article-title":"An experimental study of group opinion: the Delphi method","volume":"1","author":"Dalkey","year":"1969","journal-title":"Futures"},{"key":"10.1016\/j.cgh.2019.02.043_bib19","doi-asserted-by":"crossref","first-page":"210","DOI":"10.7326\/0003-4819-127-3-199708010-00006","article-title":"The relation between systematic reviews and practice guidelines","volume":"127","author":"Cook","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cgh.2019.02.043_bib20","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/bmj.39493.646875.AE","article-title":"Going from evidence to recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"Suppl A","key":"10.1016\/j.cgh.2019.02.043_bib21","doi-asserted-by":"crossref","first-page":"5A","DOI":"10.1155\/2005\/269076","article-title":"Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology","volume":"19","author":"Silverberg","year":"2005","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.cgh.2019.02.043_bib22","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1053\/j.gastro.2014.08.003","article-title":"Converging goals of treatment of inflammatory bowel disease from clinical trials and practice","volume":"148","author":"Levesque","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.02.043_bib23","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","article-title":"Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study","volume":"70","author":"Best","year":"1976","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.02.043_bib24","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1136\/gut.35.2.231","article-title":"Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease: a prospective multicentre study of 121 cases\u2014The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives","volume":"35","author":"Cellier","year":"1994","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2019.02.043_bib25","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ibd.20312","article-title":"Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings","volume":"14","author":"Sipponen","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.02.043_bib26","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.cgh.2008.06.010","article-title":"Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease","volume":"6","author":"Jones","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.02.043_bib27","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.cgh.2010.01.001","article-title":"Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity","volume":"8","author":"Vermeire","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.02.043_bib28","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A\u00a0simple index of Crohn's-disease activity","volume":"1","author":"Harvey","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2019.02.043_bib29","first-page":"543","article-title":"Development of the Harvey-Bradshaw Index-pro (HBI-PRO) score to assess endoscopic disease activity in Crohn's disease","volume":"5","author":"Zittan","year":"2017","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2019.02.043_bib30","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/gutjnl-2016-312648","article-title":"Development of an index to define overall disease severity in IBD","volume":"67","author":"Siegel","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2019.02.043_bib31","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1053\/j.gastro.2005.12.019","article-title":"Predictors of Crohn's disease","volume":"130","author":"Beaugerie","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.02.043_bib32","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1080\/00365520801957149","article-title":"Predictors of severe Crohn's disease","volume":"43","author":"Loly","year":"2008","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cgh.2019.02.043_bib33","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.3748\/wjg.v18.i29.3806","article-title":"Clinical, serological and genetic predictors of inflammatory bowel disease course","volume":"18","author":"Beaugerie","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cgh.2019.02.043_bib34","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/ibd.21933","article-title":"High-sensitivity C-reactive protein for identification of disease phenotype, active disease, and clinical relapses in Crohn's disease: a marker for patient classification?","volume":"18","author":"Kiss","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.02.043_bib35","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1002\/ibd.22861","article-title":"Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies","volume":"18","author":"Mao","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.02.043_bib36","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1097\/MIB.0000000000000894","article-title":"High vitamin D-binding protein concentration, low albumin, and mode of remission predict relapse in Crohn's disease","volume":"22","author":"Ghaly","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.02.043_bib37","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.12659\/MSM.897460","article-title":"Serum albumin and C-reactive protein\/albumin ratio are useful biomarkers of Crohn's disease activity","volume":"22","author":"Qin","year":"2016","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.cgh.2019.02.043_bib38","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/apt.13001","article-title":"A\u00a0retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity","volume":"41","author":"Khanna","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2019.02.043_bib39","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.1016\/S1873-9946(14)60297-X","article-title":"Patient reported outcome measures derived from the Crohn's Disease Activity Index: correlation between PRO2 and PRO3 scores and CDAI-defined clinical thresholds [abstract P176]","volume":"8","author":"Khanna","year":"2014","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2019.02.043_bib40","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/j.gastro.2009.09.056","article-title":"Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease","volume":"138","author":"Baert","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.02.043_bib41","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/ibd.20927","article-title":"Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease","volume":"15","author":"Schnitzler","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.02.043_bib42","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.gie.2005.08.011","article-title":"Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with\u00a0Crohn's disease","volume":"63","author":"Rutgeerts","year":"2006","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.cgh.2019.02.043_bib43","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.cgh.2013.09.006","article-title":"Treat to target: a proposed new paradigm for the management of Crohn's disease","volume":"13","author":"Bouguen","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.02.043_bib45","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1097\/MIB.0b013e318283a4b3","article-title":"Evolving definitions of remission in Crohn's disease","volume":"19","author":"Panaccione","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.02.043_bib46","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1136\/gutjnl-2015-309903","article-title":"IOIBD technical review on endoscopic indices for Crohn's disease clinical trials","volume":"65","author":"Vuitton","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2019.02.043_bib47","first-page":"CD010642","article-title":"Endoscopic scoring indices for evaluation of disease activity in Crohn's disease","author":"Khanna","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cgh.2019.02.043_bib48","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/ajg.2016.177","article-title":"Radiological response is associated with better long-term outcomes and is a potential treatment target in patients with small bowel Crohn's disease","volume":"111","author":"Deepak","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2019.02.043_bib49","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1007\/s00330-015-3737-9","article-title":"Grading of Crohn's disease activity using CT, MRI, US and scintigraphy: a meta-analysis","volume":"25","author":"Puylaert","year":"2015","journal-title":"Eur Radiol"},{"key":"10.1016\/j.cgh.2019.02.043_bib50","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1007\/s00330-009-1423-5","article-title":"Enteroclysis CT and PEG-CT in patients with previous small-bowel surgical resection for Crohn's disease: CT findings and correlation with endoscopy","volume":"19","author":"Minordi","year":"2009","journal-title":"Eur Radiol"},{"key":"10.1016\/j.cgh.2019.02.043_bib51","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00261-015-0360-9","article-title":"CT and MR enterography in Crohn's disease: current and future applications","volume":"40","author":"Bruining","year":"2015","journal-title":"Abdom Imaging"},{"key":"10.1016\/j.cgh.2019.02.043_bib52","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1016\/j.ejrad.2011.07.013","article-title":"Non-perforating small bowel Crohn's disease assessed by MRI enterography: derivation and histopathological validation of an MR-based activity index","volume":"81","author":"Steward","year":"2012","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.cgh.2019.02.043_bib53","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1136\/gut.2008.167957","article-title":"Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn's disease","volume":"58","author":"Rimola","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2019.02.043_bib54","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.dld.2016.09.009","article-title":"Patient preferences for inflammatory bowel disease treatment objectives","volume":"49","author":"Casellas","year":"2017","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.cgh.2019.02.043_bib55","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2147\/PPA.S32690","article-title":"Patient perspectives on the impact of Crohn's disease: results from group interviews","volume":"6","author":"Norton","year":"2012","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.cgh.2019.02.043_bib56","first-page":"947","article-title":"Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy","volume":"97","author":"Allez","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2019.02.043_bib57","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1136\/gutjnl-2012-303957","article-title":"Role of endoscopy, cross-sectional imaging and biomarkers in Crohn's disease monitoring","volume":"62","author":"Benitez","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2019.02.043_bib58","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/nrgastro.2016.128","article-title":"Current best practice for disease activity assessment in IBD","volume":"13","author":"Walsh","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.02.043_bib59","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.cgh.2015.06.001","article-title":"Defining disease severity in inflammatory bowel diseases: current and future directions","volume":"14","author":"Peyrin-Biroulet","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.02.043_bib60","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1053\/j.gastro.2016.10.005","article-title":"Advances in use of endoscopy, radiology, and biomarkers to monitor inflammatory bowel diseases","volume":"152","author":"Panes","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.02.043_bib61","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/ajg.2011.72","article-title":"Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis","volume":"106","author":"Khan","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2019.02.043_bib62","first-page":"58","article-title":"Use of antibiotics in patients with Crohn's disease: a systematic review and meta-analysis","volume":"16","author":"Su","year":"2015","journal-title":"J\u00a0Dig Dis"},{"key":"10.1016\/j.cgh.2019.02.043_bib63","first-page":"CD000299","article-title":"Anti-tuberculous therapy for maintenance of remission in Crohn's disease","author":"Patton","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cgh.2019.02.043_bib64","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1136\/gutjnl-2013-304488","article-title":"Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI)","volume":"63","author":"Dewint","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2019.02.043_bib65","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/ajg.2011.71","article-title":"Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2019.02.043_bib66","first-page":"CD008870","article-title":"Aminosalicylates for induction of remission or response in Crohn's disease","author":"Lim","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cgh.2019.02.043_bib67","first-page":"CD008870","article-title":"Aminosalicylates for induction of remission or response in Crohn's disease","author":"Lim","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cgh.2019.02.043_bib68","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/0016-5085(79)90385-8","article-title":"National Cooperative Crohn's Disease Study: results of drug treatment","volume":"77","author":"Summers","year":"1979","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.02.043_bib69","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0016-5085(84)90409-8","article-title":"European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment","volume":"86","author":"Malchow","year":"1984","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.02.043_bib70","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/00054725-200108000-00007","article-title":"Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine","volume":"7","author":"Naganuma","year":"2001","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.02.043_bib71","first-page":"917","article-title":"The effect of sulfasalazine and 5-aminosalicylic acid on the secretion of interleukin 8 by human colon myofibroblasts","volume":"72","author":"Lodowska","year":"2015","journal-title":"Acta Pol Pharm"},{"key":"10.1016\/j.cgh.2019.02.043_bib72","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/gut.22.5.404","article-title":"Effect of sulphasalazine in patients with active Crohn's disease: a controlled double-blind study","volume":"22","author":"Van Hees","year":"1981","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2019.02.043_bib73","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/apt.13190","article-title":"Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's disease","volume":"41","author":"Moja","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2019.02.043_bib74","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/ajg.2011.70","article-title":"Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and\u00a0meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2019.02.043_bib75","first-page":"CD000296","article-title":"Budesonide for induction of remission in Crohn's disease","author":"Rezaie","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cgh.2019.02.043_bib76","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.crohns.2014.01.021","article-title":"Once versus three times daily dosing of oral budesonide for active Crohn's disease: a double-blind, double-dummy, randomised trial","volume":"8","author":"Dignass","year":"2014","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2019.02.043_bib77","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.crohns.2012.06.006","article-title":"Efficacy and tolerability of oral budesonide in Japanese patients with active Crohn's disease: a multicentre, double-blind, randomized, parallel-group Phase II study","volume":"7","author":"Suzuki","year":"2013","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2019.02.043_bib78","first-page":"CD002913","article-title":"Budesonide for maintenance of remission in Crohn's disease","author":"Kuenzig","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cgh.2019.02.043_bib79","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1365-2036.2008.03891.x","article-title":"Oral budesonide for maintenance of remission of Crohn's disease: a pooled safety analysis","volume":"29","author":"Lichtenstein","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2019.02.043_bib80","first-page":"CD006792","article-title":"Traditional corticosteroids for induction of remission in Crohn's disease","author":"Benchimol","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cgh.2019.02.043_bib81","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/j.1572-0241.2002.05596.x","article-title":"Corticosteroids in Crohn's disease","volume":"97","author":"Yang","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2019.02.043_bib82","first-page":"CD000952","article-title":"Calcium and vitamin D for corticosteroid-induced osteoporosis","author":"Homik","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cgh.2019.02.043_bib83","first-page":"905","article-title":"Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease: German\/Austrian Budesonide Study Group","volume":"8","author":"Gross","year":"1996","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.02.043_bib84","first-page":"PI29","article-title":"Beclomethasone dipropionate for the treatment of mild-to-moderate Crohn's disease: an open-label, budesonide-controlled, randomized study","volume":"12","author":"Tursi","year":"2006","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.cgh.2019.02.043_bib85","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/00054725-199808000-00001","article-title":"Intravenous corticotrophin vs hydrocortisone in the treatment of hospitalized patients with Crohn's disease: a randomized double-blind study and follow-up","volume":"4","author":"Chun","year":"1998","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.02.043_bib86","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/00004836-198604000-00010","article-title":"Use of an intravenous steroid regimen in the treatment of acute Crohn's disease","volume":"8","author":"Shepherd","year":"1986","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.cgh.2019.02.043_bib87","first-page":"CD000301","article-title":"Corticosteroids for maintenance of remission in Crohn's disease","author":"Steinhart","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cgh.2019.02.043_bib88","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S1542-3565(04)00662-7","article-title":"Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease","volume":"3","author":"Schoon","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.02.043_bib89","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1053\/j.gastro.2006.01.048","article-title":"American Gastroenterological Association Institute technical review on\u00a0corticosteroids, immunomodulators, and infliximab in\u00a0inflammatory bowel disease","volume":"130","author":"Lichtenstein","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.02.043_bib90","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/ajg.2012.218","article-title":"Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry","volume":"107","author":"Lichtenstein","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2019.02.043_bib91","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/ajg.2011.64","article-title":"Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis","volume":"106","author":"Khan","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2019.02.043_bib92","first-page":"CD000545","article-title":"Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease","author":"Chande","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cgh.2019.02.043_bib93","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1155\/2014\/649465","article-title":"Canadian Association of Gastroenterology position statement regarding the use of thiopurines for the treatment of inflammatory bowel disease","volume":"28","author":"Marshall","year":"2014","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.02.043_bib94","first-page":"CD000067","article-title":"Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease","author":"Chande","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cgh.2019.02.043_bib95","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1007\/s10620-014-3419-5","article-title":"Withdrawal of long-term maintenance treatment with azathioprine tends to increase relapse risk in patients with Crohn's disease","volume":"60","author":"Wenzl","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2019.02.043_bib96","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/ajg.2013.402","article-title":"The role of thiopurines in reducing the need for surgical resection in Crohn's disease: a systematic review and meta-analysis","volume":"109","author":"Chatu","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2019.02.043_bib97","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1365-2036.2010.04330.x","article-title":"Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease","volume":"32","author":"Smith","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2019.02.043_bib98","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cgh.2010.09.016","article-title":"A\u00a0systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease","volume":"9","author":"Kotlyar","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.02.043_bib99","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/ajg.2013.451","article-title":"Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta-analysis","volume":"109","author":"Ariyaratnam","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2019.02.043_bib101","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study","volume":"374","author":"Beaugerie","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2019.02.043_bib102","first-page":"CD003459","article-title":"Methotrexate for induction of remission in refractory Crohn's disease","author":"McDonald","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cgh.2019.02.043_bib103","first-page":"2203","article-title":"Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial","volume":"92","author":"Oren","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2019.02.043_bib104","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199502023320503","article-title":"Methotrexate for the treatment of Crohn's disease: the North American Crohn's Study Group Investigators","volume":"332","author":"Feagan","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2019.02.043_bib105","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/apt.12161","article-title":"Pharmacokinetic profiles for oral and subcutaneous methotrexate in patients with Crohn's disease","volume":"37","author":"Wilson","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2019.02.043_bib106","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1046\/j.1365-2036.2003.01614.x","article-title":"Bioavailability of oral vs subcutaneous low-dose methotrexate in patients with Crohn's disease","volume":"18","author":"Kurnik","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2019.02.043_bib107","first-page":"CD006884","article-title":"Methotrexate for maintenance of remission in Crohn's disease","author":"Patel","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cgh.2019.02.043_bib108","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJM200006013422202","article-title":"A\u00a0comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease: North American Crohn's Study Group Investigators","volume":"342","author":"Feagan","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2019.02.043_bib109","first-page":"651","article-title":"Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity","volume":"32","author":"Weinshilboum","year":"1980","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.cgh.2019.02.043_bib110","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/ajg.2011.73","article-title":"Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2019.02.043_bib111","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1053\/j.gastro.2014.10.011","article-title":"Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis","volume":"148","author":"Hazlewood","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.02.043_bib112","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.mayocp.2014.08.019","article-title":"Comparative efficacy of biologic therapy in biologic-naive patients with Crohn disease: a systematic review and network meta-analysis","volume":"89","author":"Singh","year":"2014","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cgh.2019.02.043_bib113","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.02.043_bib114","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S0016-5085(99)70005-3","article-title":"Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial","volume":"116","author":"D'Haens","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.02.043_bib115","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2019.02.043_bib116","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1053\/j.gastro.2012.01.035","article-title":"Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial","volume":"142","author":"Rutgeerts","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.02.043_bib117","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","article-title":"Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial","volume":"371","author":"D'Haens","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2019.02.043_bib118","doi-asserted-by":"crossref","first-page":"14479","DOI":"10.3748\/wjg.v20.i39.14479","article-title":"Evaluation of \u201ctop-down\u201d treatment of early Crohn's disease by double balloon enteroscopy","volume":"20","author":"Fan","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cgh.2019.02.043_bib119","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/ecco-jcc\/jjv220","article-title":"Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohort","volume":"10","author":"Gecse","year":"2016","journal-title":"J\u00a0Crohns Colitis"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2019.02.043_bib120","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1586\/17474124.2015.1091308","article-title":"Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: a Norwegian observational study","volume":"9","author":"Jahnsen","year":"2015","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.02.043_bib121","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.3109\/00365521.2016.1149883","article-title":"Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis","volume":"51","author":"Keil","year":"2016","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cgh.2019.02.043_bib122","first-page":"297","article-title":"Switching from Remicade(R) to Remsima(R) is well tolerated and feasible: a prospective, open-label study","volume":"11","author":"Buer","year":"2017","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2019.02.043_bib123","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","article-title":"Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial","volume":"389","author":"Jorgensen","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2019.02.043_bib124","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/ecco-jcc\/jjw138","article-title":"Patient perspectives on biosimilars: a survey by the European Federation of Crohn's and Ulcerative Colitis Associations","volume":"11","author":"Peyrin-Biroulet","year":"2017","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2019.02.043_bib125","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1053\/j.gastro.2013.10.046","article-title":"American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-alpha biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease","volume":"145","author":"Dassopoulos","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.02.043_bib126","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.crohns.2014.07.003","article-title":"Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: a systematic review and meta-analysis","volume":"8","author":"Kopylov","year":"2014","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2019.02.043_bib127","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/apt.13838","article-title":"Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy","volume":"45","author":"Colombel","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2019.02.043_bib128","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1093\/ecco-jcc\/jjw152","article-title":"Adalimumab monotherapy and a combination with azathioprine for Crohn's disease: a prospective, randomized trial","volume":"10","author":"Matsumoto","year":"2016","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2019.02.043_bib129","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1053\/j.gastro.2013.11.024","article-title":"Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease","volume":"146","author":"Feagan","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.02.043_bib130","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.02.043_bib131","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.02.043_bib132","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","article-title":"Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial","volume":"146","author":"Sandborn","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cgh.2019.02.043_bib133","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A\u00a0short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease: Crohn's Disease cA2 Study Group","volume":"337","author":"Targan","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2019.02.043_bib134","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1053\/j.gastro.2006.02.014","article-title":"Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial","volume":"130","author":"Lemann","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.02.043_bib135","first-page":"CD006893","article-title":"Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease","author":"Behm","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cgh.2019.02.043_bib136","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/ajg.2011.60","article-title":"Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review","volume":"106","author":"Billioud","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2019.02.043_bib137","first-page":"760","article-title":"Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review","volume":"104","author":"Gisbert","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2019.02.043_bib138","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1136\/gutjnl-2014-307883","article-title":"The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease","volume":"64","author":"Vande Casteele","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2019.02.043_bib139","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/ajg.2012.363","article-title":"Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis","volume":"108","author":"Nanda","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2019.02.043_bib140","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1136\/gutjnl-2013-305279","article-title":"Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial","volume":"63","author":"Steenholdt","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2019.02.043_bib141","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/gutjnl-2011-300755","article-title":"Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial","volume":"61","author":"Van Assche","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2019.02.043_bib142","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/apt.13083","article-title":"Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed","volume":"41","author":"Gisbert","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2019.02.043_bib143","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.cgh.2016.03.038","article-title":"Comparative effectiveness and safety of anti-tumor necrosis factor agents in biologic-naive patients with Crohn's disease","volume":"14","author":"Singh","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.02.043_bib144","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1097\/MIB.0000000000000373","article-title":"Efficacy and safety of natalizumab and vedolizumab for the management of Crohn's disease: a systematic review and meta-analysis","volume":"21","author":"Chandar","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.02.043_bib145","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.cgh.2008.06.007","article-title":"Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin","volume":"6","author":"Feagan","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.02.043_bib146","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2019.02.043_bib147","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","article-title":"Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed","volume":"147","author":"Sands","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.02.043_bib148","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/ajg.2016.236","article-title":"The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn's disease: results from the US VICTORY Consortium","volume":"111","author":"Dulai","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2019.02.043_bib149","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/01.MIB.0000480052.94783.fd","article-title":"Evidence of mucosal healing in patients with Crohn's disease treated with open-label vedolizumab: a case series [abstract P-006]","volume":"22","author":"Shafran","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.02.043_bib150","doi-asserted-by":"crossref","first-page":"S804","DOI":"10.1016\/S0016-5085(16)32722-6","article-title":"Mucosal healing and dysplasia surveillance in a large referral center cohort of patients with Crohn's disease and ulcerative colitis treated with vedolizumab [abstract Mo1880]","volume":"150","author":"Noman","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.02.043_bib151","first-page":"S-277","article-title":"Efficacy of vedolizumab with concomitant corticosteroid or immunomodulator use in patients with Crohn's disease from GEMINI 2 [abstract Sa1270]","volume":"148","author":"Colombel","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.02.043_bib152","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/apt.13243","article-title":"Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease","volume":"42","author":"Rosario","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2019.02.043_bib153","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/S1873-9946(14)60083-0","article-title":"Pharmacokinetic and pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: additional results from the GEMINI 1 and 2 studies [abstract DOP058]","volume":"8","author":"Rosario","year":"2014","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2019.02.043_bib154","first-page":"412","article-title":"Long-term efficacy of vedolizumab for Crohn's disease","volume":"11","author":"Vermeire","year":"2017","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2019.02.043_bib155","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/MIB.0000000000000979","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease in patients naive to or who have failed tumor necrosis factor antagonist therapy","volume":"23","author":"Sands","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.02.043_bib156","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn's disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2019.02.043_bib157","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1053\/j.gastro.2008.07.014","article-title":"A\u00a0randomized trial of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease","volume":"135","author":"Sandborn","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.02.043_bib158","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn's disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2019.02.043_bib159","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2019.02.043_bib160","first-page":"CD007572","article-title":"Anti-IL-12\/23p40 antibodies for induction of remission in Crohn's disease","author":"Khanna","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cgh.2019.02.043_bib161","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.cgh.2015.09.018","article-title":"Subcutaneous ustekinumab provides clinical benefit for two-thirds of patients with Crohn's disease refractory to anti-tumor necrosis factor agents","volume":"14","author":"Wils","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.02.043_bib162","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1097\/MIB.0000000000000842","article-title":"Ustekinumab for the treatment of refractory Crohn's disease: the spanish experience in a large multicentre open-label cohort","volume":"22","author":"Khorrami","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.02.043_bib163","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/MIB.0000000000000624","article-title":"Patients with refractory Crohn's disease successfully treated with ustekinumab","volume":"22","author":"Harris","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.02.043_bib164","first-page":"473","article-title":"Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease","volume":"7","author":"Ghouri","year":"2014","journal-title":"Clin Exp Gastroenterol"},{"key":"10.1016\/j.cgh.2019.02.043_bib165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12328-013-0440-8","article-title":"Probiotic treatments for induction and maintenance of remission in inflammatory bowel diseases: a meta-analysis of randomized controlled trials","volume":"7","author":"Fujiya","year":"2014","journal-title":"Clin J Gastroenterol"},{"key":"10.1016\/j.cgh.2019.02.043_bib166","first-page":"CD006634","article-title":"Probiotics for induction of remission in Crohn's disease","author":"Butterworth","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cgh.2019.02.043_bib167","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1007\/s10620-007-0171-0","article-title":"A\u00a0meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease","volume":"53","author":"Rahimi","year":"2008","journal-title":"Dig Dis Sci"},{"issue":"Suppl 2","key":"10.1016\/j.cgh.2019.02.043_bib168","doi-asserted-by":"crossref","first-page":"S240","DOI":"10.1017\/S0007114512001626","article-title":"Omega-3 fatty acids and inflammatory bowel diseases: a systematic review","volume":"107","author":"Cabre","year":"2012","journal-title":"Br J Nutr"},{"key":"10.1016\/j.cgh.2019.02.043_bib169","first-page":"CD006320","article-title":"Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease","author":"Lev-Tzion","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cgh.2019.02.043_bib170","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.cgh.2013.04.034","article-title":"Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study","volume":"11","author":"Naftali","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.02.043_bib171","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/01.MIB.0000440982.79036.d6","article-title":"Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn's disease","volume":"20","author":"Storr","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.02.043_bib172","first-page":"CD010410","article-title":"Low dose naltrexone for induction of remission in Crohn's disease","author":"Segal","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cgh.2019.02.043_bib173","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/gut.2005.080887","article-title":"Mu opioid receptor expression is increased in inflammatory bowel diseases: implications for homeostatic intestinal inflammation","volume":"55","author":"Philippe","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2019.02.043_bib174","first-page":"CD007348","article-title":"Glutamine for induction of remission in Crohn's disease","author":"Akobeng","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cgh.2019.02.043_bib175","first-page":"CD005984","article-title":"Enteral nutrition for maintenance of remission in Crohn's disease","author":"Akobeng","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cgh.2019.02.043_bib176","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1177\/1756283X15578607","article-title":"Specialized enteral nutrition therapy in Crohn's disease patients on maintenance infliximab therapy: a meta-analysis","volume":"8","author":"Nguyen","year":"2015","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.cgh.2019.02.043_bib177","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/gut.35.3.360","article-title":"Frequency of glucocorticoid resistance and dependency in Crohn's disease","volume":"35","author":"Munkholm","year":"1994","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2019.02.043_bib178","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0016-5085(90)90002-I","article-title":"Clinical, biological, and endoscopic picture of attacks of Crohn's disease: evolution on prednisolone\u2014Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","volume":"98","author":"Modigliani","year":"1990","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.02.043_bib179","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1053\/j.gastro.2013.06.009","article-title":"Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease","volume":"145","author":"Panes","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.02.043_bib180","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1053\/j.gastro.2013.04.048","article-title":"Early administration of azathioprine vs conventional management of Crohn's disease: a randomized controlled trial","volume":"145","author":"Cosnes","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.02.043_bib181","first-page":"981","article-title":"Tolerability profile of thiopurines in inflammatory bowel disease: a prospective experience","volume":"52","author":"Macaluso","year":"2017","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cgh.2019.02.043_bib182","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.cgh.2014.02.026","article-title":"Increased risk of acute myeloid leukemias and myelodysplastic syndromes in patients who received thiopurine treatment for inflammatory bowel disease","volume":"12","author":"Lopez","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.02.043_bib183","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1136\/gutjnl-2013-305763","article-title":"Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer","volume":"63","author":"Beaugerie","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2019.02.043_bib184","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1097\/MIB.0000000000000923","article-title":"Experts opinion on the\u00a0practical use of azathioprine and 6-mercaptopurine in inflammatory bowel disease","volume":"22","author":"Mottet","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.02.043_bib185","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1007\/s12325-017-0545-4","article-title":"Predicting pre-emptive discussions of biologic treatment: results from an openness and preference survey of inflammatory bowel disease patients and their prescribers","volume":"34","author":"Kariburyo","year":"2017","journal-title":"Adv Ther"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356519302538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356519302538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:28:31Z","timestamp":1761542911000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356519302538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":183,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S1542356519302538"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2019.02.043","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn\u2019s Disease","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2019.02.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the AGA Institute and the Canadian Association of Gastroenterology","name":"copyright","label":"Copyright"}]}}